Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. [electronic resource]
Producer: 20120618Description: 551-7 p. digitalISSN:- 1473-5571
- ADP-ribosyl Cyclase 1 -- drug effects
- Adult
- Antiretroviral Therapy, Highly Active -- methods
- CD4 Lymphocyte Count
- Case-Control Studies
- Fas Ligand Protein -- drug effects
- Flow Cytometry
- HIV Infections -- drug therapy
- HIV Integrase Inhibitors -- therapeutic use
- Humans
- Leukocyte Common Antigens -- drug effects
- Middle Aged
- Platelet Endothelial Cell Adhesion Molecule-1 -- drug effects
- Pyrrolidinones -- therapeutic use
- Raltegravir Potassium
- TNF-Related Apoptosis-Inducing Ligand -- drug effects
- Treatment Outcome
- Tumor Necrosis Factor Receptor Superfamily, Member 7 -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.